Quarterly report
Open the filing on sec.gov
Amneal Pharmaceuticals, Inc. (AMRX)
Nasdaq: AMRX · Pharmaceutical Preparations · filing with the SEC since 2017
Grade5.3
◀ Past 4.9● Present 6.3▶ Future 4.3
The companyfiscal 2025, as filed
Revenue$3.02B+8.0%
Net income$72.1M+161.6%
Earnings per share$0.22+157.9%
Operating cash flow$340M+15.2%
Cash$282M+155.1%
Debt$2.57B+7.8%
Shareholders’ equity-$70.8M+35.2%
Shares, diluted324.8M+5.1%
Return on equityn/a
The recordfrom its filings
Filings in 202676
Newest filingNov 9 · 10-Q
Annual reportFeb 27, 2026
Quarterly reportNov 9, 2026
Next report due10-K by Mar 1
Insider sales, 12 months$9.8M
Insider buys, 12 months$0.00
Patents granted69
Filer categoryLarge accelerated filer
Trailing twelve months to Sep 2026Revenue $3.20BNet income $133MCash from operations $181Mthe four newest filed quarters added
Left: the newest annual report, with the change on the year before. Right: counted from the company's own filings with the SEC.
As filed, in USD. Nothing here is a forecast.
News
Results released
Open the filing on sec.gov
Current report, amended
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Shelf registration
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Insider trade report
Open the filing on sec.gov
Nothing of this kind is on the record for this company yet.
An outside story is shown by its headline, its source and its link only. The SI reads the page when you ask it to break one down.